Full Business Value: Galapagos Corp (GLPG)

European biotech Galapagos NV (GLPG) specializes in discovering new molecules to combat inflammation and cancer, while colossal investments in science and stringent oversight from US and EU regulators create an insurmountable barrier for competitors. This price chart on the GURU.Markets platform reflects an Enterprise Value of -1685.53, as the company optimizes costs by updating its pool of early-stage research contractors.

glpg.com (GLPG): Total Company Value from 11/23/2025 to 05/08/2026

Galapagos NV (GLPG) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Galapagos N.V.|GLPG - Price Target Chart

- company stock exchange capitalization indicators:

Market Valuation Galapagos|GLPG - Enterprise Value

- book capitalization indicators:

Book Value of One Share Galapagos|GLPG - Company Book Value|Market Capitalization to Net Assets glpg.com|GLPG - Company Total Assets

- business debt structure and liquidity details:

- net income and valuation ratios data:

GLPG - Net Income

Analysis of all company metrics:Galapagos N.V.

For Galapagos NV (GLPG), whose valuation depends on regulatory decisions regarding new drugs during the loss of exclusivity for older ones, the current EV reflects the actual cost of acquiring the business. By summing market capitalization and net debt, this indicator allows investors to assess the company's actual capital, separating market optimism from the debt load amid the transformation of the biotechnological ecosystem.

Competitors of Galapagos NV (GLPG)

Haleon PLC - Total Company Value|KVUE - Total Company Value|Full Business Value VRNA|MENS: Enterprise Value|Full Takeover Company Value ligand.com LGND|Total Company Value Amneal|Perrigo Company PLC - Full Business Value|Enterprise Value ALVO|LQDA (Liquidia Inc.) - Value Adjusted for Debt and Cash|Enterprise Value ANIP (ANI Pharmaceuticals)|Enterprise Value mannkindcorp.com MNKD|AMPH - Total Company Value|Value Adjusted for Debt and Cash PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Total Company Value|Real Price to Acquire Entire Company Theravance Corp|AQST (Aquestive Therapeutics) - Enterprise Value|Enterprise Value scPharma|Real Price to Acquire Entire Company TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharma) - Value Adjusted for Debt and Cash|Total Company Value China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Total Enterprise Value|BHST: Real Price to Acquire Entire Company|invizyne.com - Aggregate Business Value|ORMP: Enterprise Value|Entera Bio - Value Adjusted for Debt and Cash|HYFT (MindWalk) - Enterprise Value|Total Enterprise Value ABVC BioPharma, Inc ABVC|Total Company Value Cumberland Pharmaceuticals (CPIX)|QNTM (quantumbiopharma.com) - Value Adjusted for Debt and Cash|Enterprise Value FGEN (FibroGen)|Full Takeover Company Value Telomir Pharmaceuticals Inc|Rani Therapeutics Inc - Enterprise Value|SNYR - Enterprise Value|rallybio.com (RLYB) - Total Company Value|LEXX (Lexaria Bioscience Corp.) - Total Company Value|PULM (Pulmatrix) - Enterprise Value|Enterprise Value Pheton|Total Company Value Aptorum Group Limited (APM)|LYRA: Full Business Value|Enterprise Value IBO (Impact BioMedical)|Enterprise Value TNF Pharmaceuticals Inc. TNFA|cbdMD Corp - Enterprise Value|Full Takeover Company Value PainReform Ltd (PRFX)|altamiratherapeutics.com (CYTO) - Total Company Value|Total Enterprise Value Lipella Pharma (LIPO)|Total Company Value OptiNose, Inc.|pieris.com (PIRS) - Company Buyout Price|Real Price to Acquire Entire Company PROC (Procaps)|PTPI (Petros Pharmaceuticals Inc) - Value Adjusted for Debt and Cash|Total Company Value Qilian International Holding Group Limited QLI|SLRN: Business Value|TFFP: Real Price to Acquire Entire Company